myocardial ischemia
We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of vascular endothelial growth factor (VEGF) as sole therapy for patients with symptomatic myocardial ischemia.
We initiated a phase 1 clinical study to determine the safety and bioactivity of direct myocardial gene transfer of <span class="gene" id="9860779-1-116-150">vascular endothelial growth factor</span> (<span class="gene" id="9860779-1-152-156">VEGF</span>) as sole therapy for patients with symptomatic <span class="disease" id="9860779-1-204-223">myocardial ischemia</span>.